PSA welcomes expansion of FluMist program for NSW children

27 May 2026

 

The Pharmaceutical Society of Australia (PSA) has today welcomed the New South Wales Government’s expansion of the funded FluMist Nasal Spray Influenza Vaccination Program to improve access to the influenza vaccine for children aged 2-17.  

 

From Wednesday 27 May, the total doses available under the Nasal Spray Influenza Vaccination Program will increase from 8,000 to 11,000. 

 

PSA NSW President, Luke Kelly FPS, said the expansion is a step in the right direction to improving vaccination accessibility, particularly for young families.  

 

“With Winter coming up, now is the time to get vaccinated against influenza,” he said.  

 

“Having alternative vaccination methods is a positive move that we expect will improve child and adolescent vaccination rates this year.  

 

“I encourage parents to talk to their pharmacist to see which vaccination method is most suitable for their child or children ahead of the 2026 flu season.”  

 

The PSA acknowledges that pharmacists are well placed to deliver vaccinations safely and conveniently and will continue to advocate for expanded pharmacist-delivered vaccination services.  

 

 

 

Media contact: Leah Jacobsen 

M: 0480 099 798 E: leah.jacobsen@psa.org.au 

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.